Licensing of specs and artifacts

Hi everyone,

In light of the recent re-licensing of FHIR using the Creative Commons CC0 Public Domain Dedication as well as the discussion about licensing at the 2014 openEHR Roadmap Meeting in Lillestrøm on September 16 and 17, I’d like to restart the discussion on licensing of openEHR specifications and artefacts (mainly archetypes, but also potentially templates and terminology sets).

As of now, the specifications are licensed using the Creative Commons Attribution No-Derivatives (CC-B-ND) license, while the Creative Commons Attribution Share-Alike (CC-BY-SA) is used for artefacts. Several issues have been raised about this choice of licences. Feel free to add to this list, I’m bound to have forgot some issues:

CC-BY-ND (for specs):

· Theoretically, a hostile takeover of the openEHR Foundation might leave the openEHR specs dead, as with the CC-BY-ND only the copyright holder (the Foundation) has the rights to modify them. A forkable license like for instance CC-BY-SA would solve this issue. Global registering of the openEHR trademark would keep any derivates to be branded as “openEHR”.

CC-BY-SA (for artefacts):

· Commercial implementers might avoid using CC-BY-SA artefacts because the license requires any published modifications of the work to be licensed using the same license. This might lead implementers to believe the license would require them to license their entire software product as CC-BY-SA. There are several examples of CC-BY-SA works being used in copyrighted works, such as Wikipedia articles being used in newspapers, but this is probably reliant on a benign licensor, which any normal commercial company can’t rely 100% on. The way I see it, this problem could be solved in one of two ways:

o Use the CC-BY license, which retains the attribution clause, but doesn’t require any derivative works to use the same license. This has the disadvantage of enabling proprietary tweaking of archetypes, which could potentially ruin interoperability.

o Retain the CC-BY-SA license, but add an explicit clause that allows all implementers to use artefacts in closed-source, proprietary products with any license they like. Artefacts published by themselves, as standalone archetypes, templates or terminology sets would still be bound by the ShareAlike clause. This is supported by Creative Commons via the CC+ protocol.

I realise these issues will ultimately be decided by the board of the openEHR Foundation, but if the community can come to some kind of consensus on this issue I would hope it’d send them a strong signal.

Kind regards,
Silje Ljosland Bakke

Coordinator, National Editorial Board for Archetypes, National ICT Norway
Adviser, R&D dept, E-health section, Bergen Hospital Trust

Tel. +47 40203298

Thanks Silje, that you bring this very important subject under attention.

It was already under attention recently on a LinkedIn discussion, but I am afraid it did not reach the right people.

I do agree with your point of view, so there is not much discussion, there is only one small remark. I don't see any point in retaining the CC-BY-SA license, with extra clause.

First, CC-BY-SA prevents the secret proprietary use of OpenEHR-archetypes, in industry this can be a reason not to use OpenEHR.
Except from that, CC-BY-SA is not by everyone understood and is a source of FUD (Fear, Uncertainty, Doubt), even with extra clause, it will remain a source of FUD.

For information the link to the LinkedEhr discussion, I hope it works

https://www.linkedin.com/groups/Membership-144276.S.5909661200660054019?trk=groups_most_popular-0-b-ttl&goback=.gde_144276_member_5909661200660054019.gmp_144276

Best regards
Bert Verhees

"For information the link to the LinkedEhr discussion, I hope it works"

Of course, this should be: LinkedIN :wink:

(sorry David)

Best regards
Bert Verhees

Hahaha, it’s good you always have LinkEHR in mind :wink:

By the way, this is certainly an old and recurring topic. I have checked that there were already discussions back in 2009, so probably we are going to repeat things already commented.

I will talk about artefacts (archetypes). The first thing to solve in my opinion is to agree on what does “derivative work” mean for an archetype. Is just modified archetypes? Auto-generated data base schemas, validation schematron or other technical artefacts? Documentation describing the archetype? I would love to say that only the first case applies, but let’s thing in an example. Which is the license for a movie you make from a CC-BY-SA book? It is for sure a derivative work, and the Title 17 Section 101 of the Copyright Act of the United States says it very clear:

“A derivative work is a work based upon one or more preexisting works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which a work may be recast, transformed, or adapted. A work consisting of editorial revisions, annotations, elaborations, or other modifications which, as a whole, represent an original work of authorship, is a derivative work.” (http://www.law.cornell.edu/uscode/text/17/101)

Given that definition I don’t think a technical transformation of an archetype is a different case. So yes, I’m not a lawyer, but I would say that fears of implementers of commercial products using openEHR archetypes are reasonable if the the CC-BY-SA license is applied as is.

David

At the end of the day, I don't really care what licence is used for these things in openEHR - maybe the community should just vote. The long debates from the past are summarised here <http://www.openehr.org/wiki/display/oecom/Archetype+licensing+-+the+case+for+CC-BY-SA&gt; and here <http://www.openehr.org/wiki/display/oecom/openEHR+Transition+Feedback+Page&gt;\. This page <http://www.openehr.org/wiki/display/oecom/openEHR+IP+License+Revision+Proposal&gt; contains one attempt I made to state the requirements for each kind of openEHR IP.

Nevertheless, here are some new thoughts, based on a review of CC-BY-SA 4.0....

I think the key things to remember in resolving this are how the various artefacts get used, which helps figure where 'adaptation' actually exists. I can think of the following:

  * archetype => template => software application
      o the simplest standard practice
      o this is USE not ADAPTATION
  * archetype => specialise => template => software application
      o the next simplest standard practice
      o this is USE not ADAPTATION
  * archetype => software application
      o not a great idea in general - it means that the 'archetypes' are
        not really maximal re-usable data sets, but something like
        predefined templates. However, someone is bound to do this, and
        produce a good product from it.
      o this is USE not ADAPTATION
  * archetype => forking => modification => templating => software
    application
      o Result: probably non-interoperable data; but may occur for
        pragmatic reasons, e.g. openEHR is too slow to make fixes to the
        archetype.
      o this is ADAPTATION

According to the CC-BY-SA 4.0 licence text only the last of these paths means that the final software or other result is an 'adaptation' of the original archetype, which means that the CC-BY-SA license applies, IF YOU PUBLICLY SHARE THE ARTEFACT.

Here is relevant licence text from the CC site <https://creativecommons.org/licenses/by-sa/4.0/legalcode&gt; (my bolding):

1. *Adapted Material*means material subject to Copyright and Similar
    Rights that is derived from or based upon the Licensed Material and
    in which the Licensed Material is *translated, altered, arranged,
    transformed, or otherwise modified *in a manner requiring permission
    under the Copyright and Similar Rights held by the Licensor. For
    purposes of this Public License, where the Licensed Material is a
    musical work, performance, or sound recording, Adapted Material is
    always produced where the Licensed Material is synched in timed
    relation with a moving image.
2. *Share*means to provide material to the public by any means or
    process that requires permission under the Licensed Rights, such as
    reproduction, public display, public performance, distribution,
    dissemination, communication, or importation, and to make material
    available to the public including in ways that members of the public
    may access the material from a place and at a time individually
    chosen by them.

This is why we choose CC-0 for FHIR. End of story, there are no debates.

Sure, people can go and try and make money off FHIR. All power to
them. But times have changed - if they're intending to compete, they
won't stay ahead of the community nowadays. So anyone worth working
with will share the common stuff, and focus on making money using and
leveraging our IP. Which is what we want to happen.

Other people have raised the concern that people will be able predate
the work and take it away from us. Not so. They have confused
trademark, patents, and copyright. We yielded copyright. Trademark we
explicitly did not, and patents.... that's a complicated story of it's
own. But public prior art is the best defense against patents, and
FHIR is busy creating public prior art. Of course, openEHR has been
doing so for a lot longer

Grahame

Just to be clear, I repeat that that is exactly what I would like to
interpret. But if I read the legal texts trying to be objective (and again,
not being a lawyer!) it is normal that doubts arise. If I generate a
validation software that includes validation rules from the archetype
constraints, that is arguably an adaptation, not just a use.

And it is also important to note that if you sell a software you are also
publicly sharing it. Publicly share does not imply for free, but outside of
a personal use.

I fully support the comments of Grahame. Probably the solution is to go
just for the simpler option and don't worry about what others do with their
own business.

Grahame,

we should certainly examine the discussions you have had in FHIR-land. Is there a link to any discussion, debate on this (i.e. we know what the result it, but what was the thinking along the way?)

- thomas

this actually seems to be the most important point. The following definition, (especially the last bit) of ‘share’ doesn’t mention commercial sale, and to me it doesn’t read as if selling could be included: Does anyone know definitively if this commercial sale is meant to be included here? I also incline to the same opinion… - thomas

hi

we should certainly examine the discussions you have had in FHIR-land.

The discussions were all private threads, but I can give you a summary
run down. We start with our plain english license:

* FHIR is © and ® HL7. The right to maintain FHIR remains vested in HL7
* You can redistribute FHIR
* You can create derivative specifications or implementation-related
products and services
* Derivative Specifications cannot redefine what conformance to FHIR means
* You can't claim that HL7 or any of its members endorses your derived
[thing] because it uses content from this specification
* Neither HL7 nor any of the contributors to this specification accept
any liability for your use of FHIR

Our intent here is a license for a standard: lots of commercial
companies are going to be forced to use it (eventually), and lots of
open source applications too. What can we do to make that easy? Well,
we let anyone do anything, as long as they can't grab control of the
actual spec. For FHIR, at least, that's vested in HL7, so when we
think about grabbing control, we think in terms of "from HL7".

There's another set of considerations there too: with a lot of
existing specifications, implementation guides - which are very
derivative works - are in a grey zone. In fact, my opinion is the bulk
of Australian HL7 derived standards are not ok against the HL7 license
(and lots of other IGs too...), but HL7 affiliates don't push the
issue because we want adoption. Well, they don't usually push the
issue - and if they do, it's extremely self-destructive. But we wanted
to be explicit and clear: whatever you need to do in an implementation
guide, go do it with no worry about 'surprises' later (they tend to be
expensive$$$$). The outcome is what matters: you use our common
standard, and it's good for you, us, the providers and the consumers.
Oh, and, btw we also need to assure implementers that HL7 will not be
a capricious or undeserving steward of the work, so we don't try and
come up with some exclusivity with the license, whereby some
derivatives are ok, and some aren't. Whatever people want, that's
fine. We'll just be the best steward we can be.

So we started with that notional agreement. Which, I must say, seems
to me to apply to openEHR. I know that there's some in the community
who think that there should be some limits to commercial use for one
reason or another, or that if companies 'benefit' from the community,
they should be obliged to put back in (a Stallman kind of thing, but I
think that's self-limiting. we all have to earn a buck). It seems to
me that this kind of thinking doesn't apply to openEHR - the goals are
to help exchange health data, and unless there's some collective
fantasy that people are going to start providing healthcare for free,
it's always going to have a commercial element.

So we knew what we wanted. Initially, we considered the available CC
licenses, and others, and rejected them because they didn't have
anything in them about redefining conformance to the publication. As a
work around we adapted a license from the OMG, but that's not really
open, and it was generating problems for us because
- the fine print didn't quite say what we said in plain English
- because it wasn't a standard license, people needed to review it /
pay for lawyers to review it
- using a non-standard license meant that some purists claimed we
weren't really open

I wanted to fix that, but the process of getting lawyer time and
dealing with the organizational approval process just seemed like too
big a mountain to climb

So Paul Biondich from OpenMRS got in contact with me, and offered to
pay for lawyer time to resolve this (I really appreciated that). His
lawyer (Larry Rosen) and I went back and forth on the plain english
license making sure that he understood exactly what we wanted. For
instance, our conformance thing wasn't a play for total control of the
eco-system (unlike some other companies), just a play to retain
control over the specification. Once he was clear what we wanted, he
pointed us at CC-0 - it does what we want (btw, Larry would like us to
do more about patents - as would I - but that really is a mountain too
big to climb). When I raised the issue of conformance not being
covered by the license, he pointed out that this is a not a *copy*ing
issue, but a *control of meaning*, e.g. trademark issue.

So we agreed that we would (a) adopt CC-0 and (b) beef up the
trademark protection. HL7's own lawyer wasn't really comfortable with
allowing derivative works, but that was actually an issue with our
intent. We need to allow derivative works because there's too many
things that should be allowed that a reasonably described as
derivative works. So I proposed this to HL7, and Chuck Jaffe (HL7 CEO)
took on the herculean task of steering that change through the
organization (it should have been straight forward because we weren't
changing the intent, but these things never are straight forward). We
beefed up the procedural stuff around trademark protection further
during that process, but not much else changed; it was mainly an
educative process.

So that's the background. The key question is to agree what you want
to achieve; the exact license is a vehicle, not a goal.

My personal opinion is that openEHR should do what FHIR has done, and
for the same reasons: you should want everyone to use the work without
hesitation, but you don't want someone to try and grab control from
the community. So, I think openEHR should find a partner in the US to
hold the openEHR trademark - something that big corporates couldn't
ignore. IHTSDO, HL7, AMIA, something. And then adopt CC-0.

I really like where we are now because when the open source people
come my way, I can tell them that we're really really unencumbered in
a way that they haven't go the guts to do. They still insist on
attribution etc. So there!

Grahame

Grahame,

thanks for this, it's very useful. Some questions...

*Controlling Conformance*: CC-0 just means 'public domain', no copyright. How do you exert any kind of control (which you mention) over the conformance not being messed with? Is it just that 'FHIR' is stamped on everything, and trademark protection actually defines the rights of use? In which case, aren't we talking about some other piece of legalese to do with the trademark, that defines when something could have a 'FHIR' trademark on it?

*Copyright*: I don't see any harm in having a copyright notice if the original author(ity) demands it, e.g. Nehta is like this. Copyright is kind of useless in the land of software and formal models anyway, it's the licence that counts.

*Attribution*: Current thinking has been that if archetypes are copyrighted to whomever, the licence-to-use would require attribution, which just means listing authors. I think the value here is that artefact users know that wide consultation and expertise went into the artefact. Consider for example the BP archetype in CKM:

Would't that 'contributors' list disappear under the new FHIR approach? I think that would be a problem for openEHR - the contributors list is the main way that users can get some idea of the quality of the thing.

- thomas

(attachments)

bejcgidi.png

But some ‘derived’ artifacts should also list the original contributors as authors? Doesn’t make much sense to me.

(attachments)

bejcgidi.png

Controlling Conformance: CC-0 just means ‘public domain’, no copyright. How do you exert any kind of control (which you mention) over the conformance not being messed with?

The point of a trademark is that you can control what the name means. We say that we define what conformance to “FHIR” means. We expect that conformance will be messed with - that’s just how it works. But no one else is allowed to say what it means to be “conformant to FHIR” because hl7 owns that trademark

Also, we don’t assert any rights around copying, but that doesn’t mean that hl7 isn’t the recognised author.

Copyright: I don’t see any harm in having a copyright notice if the original author(ity) demands it, e.g. Nehta is like this. Copyright is kind of useless in the land of software and formal models anyway, it’s the licence that counts.

Well, the way I understand it, with FHIR now, someone can asset a copyright on a derived work, but they could not effectively enforce copyright provisions on the content they include from the FHIR spec. There might not be much left…

Attribution: Current thinking has been that if archetypes are copyrighted to whomever, the licence-to-use would require attribution, which just means listing authors. I think the value here is that artefact users know that wide consultation and expertise went into the artefact.

I don’t think there’s any relationship between attribution and copyright. We could choose to attribute if we wanted to. Actually, we do it at the spec level: http://hl7.org/implement/standards/fhir/credits.html#credits

Would’t that ‘contributors’ list disappear under the new FHIR approach?

No, they’re still the contributors.

Thank you Grahame for sharing the HL7 FIHR licensing experience!

This actually changes the game!

Short version:
Whatever openEHR does will now be compared to what HL7 actually has allowed for FIHR. If we with openEHR are less open than FIHR, then we’ll need to defend that position somehow, which will be hard. For example “Why do the FIHR guys trust their community, implementers and users more than openEHR does? What is the hidden agenda of openEHR?”

Long version:
Since Linkedin is not an open forum, I here post an edited and updated version of my contribution to that discussion.

I agree there has been a lot of misunderstandings and FUD [http://en.wikipedia.org/wiki/Fear,_uncertainty_and_doubt] regarding the openness of openEHR. In fact openEHR is already more open than many other technical standards/specifications that many companies and governments use without much hesitation. Regarding licensing I and others tried to explain some years ago that there might actually be some scenarios with CC-BY-SA archetypes that might be reasons for (somewhat far-fetched) fear among closed source vendors.

Please read the following two wiki-pages including the comments below them if you have not already…

  1. http://www.openehr.org/wiki/display/oecom/openEHR+IP+License+Revision+Proposal
  2. http://www.openehr.org/wiki/display/oecom/Archetype+licensing±+the+case+for+CC-BY-SA

…so that we do not need to repeat too much of the discussions once again. There you can find the openEHR statement about the intention apply the SA-clause only to derived archetypes, not to other derived things. (You can also read my comment discussion about how the SA-clause is either contagious anyway or easily circumvented.)

The main conflicts visible in the wiki-pages above concern the license of archetypes, not the specification documents (since they were under another kind of license by then, more “forkable” than the current CC-BY-ND).

Some FUD/fears might be counter-argumented by the fact that, even if CC-BY-SA for archetypes could theoretically be interpreted as imposing SA on some other downstream artifacts than archetypes, (proprietary software for example) this would never become a problem unless the copyright owner (openEHR) wants to take somebody to court, and they (the openEHR board?) clearly says in writing that they won’t for the uses they have described in the wikipages linked above. (Also as Grahame pointed out, it would be self-destructive.) To use openEHR-copyrighted CC-BY-SA archetypes you only need to trust openEHR the same way you need to trust other organizations you depend on. Once the openEHR foundation has more understandable governance (and is accountable to members, or something similar) then that will be a bit easier.

My personal conclusion of the licensing debate at the time (2011) was that there was no point in continuing it until there was another board elected that could/wanted to weigh Sam’s arguments against other people’s arguments, thus I focused on other things. I do think that Sam’s intentions/fears (e.g. to avoid hostile lock-in of archetype design-space) were understandable all through this, but that he was trying to use the wrong tool (a homegrown modification of CC-BY-SA) to achieve that goal.

Now, a probably worse problem is that by using CC-BY-SA for the international CKM archetypes for several years, openEHR has set an example that others follow in other CKM equivalents where the copyright owner could instead be a national organization (e.g. NETHA), a care provider or a company. (Perhaps even a company that gets bought by a “copyright/patent troll” that makes a mess by unjustified lawsuits.)

If everybody used something as free as CC-BY or CC-0 for archetypes etc. it would not matter if the copyright-owner could be trusted over time or not. You would then not need to convince organizations to “please assign the copyright to openEHR” before sharing your works with the world (e.g. on the openEHR CKM). But a company might have a hard time understanding why their published/shared archetypes should be either copyright-assigned to openEHR or released under CC-BY or CC-0, when the openEHR foundation itself uses CC-BY-SA. Why share the company’s archetypes with no (SA-)strings attached when the foundation has (SA-)strings attached to their gifts… [Computer nerd clarification: I here mean strings as in the saying “no strings attached”, not strings in the “datatype” sense of the word :-)]

Now let’s switch subject to from archetypes to the ND-clause on the technical specification documents, I think CC-BY-ND is more restrictive regarding forking than the previous homegrown openEHR licenses were (that allowed relicensing under other licenses). Thus the fact that forking has occurred previously does not say anything about the current “forkability” of the specs. The fact that openEHR did not make a lot of fuzz regarding the previous forks might however say something positive about openEHR.

The fact that W3C licensing disallows forks does not dictate that openEHR needs to go the same direction. Using only CC-BY or CC-0 on the specs might be a good FUD-killer, nobody then needs to trust that openEHR governance will stay fit in the future. If the openEHR organization gets overtaken or deadlocked, then forking can occur and progressive people/companies that want to develop new improved versions can do that (if they call the new thing something else than openEHR). Whether such possibilities put bad or healthy pressures on an organization is of course open to debate. W3C seems to see forking as a risk or consider themselves big/trusted enough to not get deadlocked/overtaken. Many open source projects on the other hand see forking-possibilities as a healthy emergency safeguard against potentially poor future governance/leadership.

I agree with Bert in the Linkedin-discussion, that it will most likely be possible to continue creating openEHR-compatible software from currently published CC-BY-ND licensed specifications, even if there is a “hostile takeover” or deadlock of the organization. Especially if all computable specification items (class definitions etc.) are released under Apache 2 license (I believe that is the current intention). What is published is already out there and free to use, it can never be taken back.

The ND-clause mainly causes problems for those that in a deadlock/takeover situation want to fork the project and keep working on new future/updated versions of the specification. What the ND actually in practice would protect openEHR against is less obvious to me though. Thus the ND only adds to the confusion/FUD without bringing any obvious big benefit. (W3C gets away with it though.) Compatibility issues are better managed through testing and certification than licensing. Licenses won’t stop errors, or non-conformance.

Phew… amazing if you had the energy to read all the way down to here.

Tom, regarding what it means to sell Share-Alike (SA) artifacts, I think you can compare that to http://www.gnu.org/philosophy/selling.html

Best regards,
Erik Sundvall
Ph.D. Medical Informatics. Information Architect. Tel: +46-72-524 54 55 (or 010-1036252 in Sweden)
LiÖ: erik.sundvall@lio.se http://www.lio.se/itc/ & http://www.lio.se/testbadd
LiU: erik.sundvall@liu.se http://www.imt.liu.se/~erisu/

Is there going to be a follow up on this discussion?
Will we here something about it?

Bert

I refloat this thread as I think I got a practical use case: I have
generated a transformation from openEHR archetypes to ISO13606
archetypes. I have a couple of questions about the resulting ADL.
The copyright holder is still openEHR? Does It have something to do
with the CC-BY-SA license?
What license was decided we should use? Did we agree in which metadata
field should we store this?
Does the author change? Probably the source archetype will also need
to be referenced somehow. What else should be changed/added?
I assume that also a 'generated' field should be added (I know ADL 2
has this as a explicit field :wink: so for the moment probably the best is
to store everything we can't put elsewhere in "other_details".

Can the resulting ADL be publicly distributed?

Hi Diego,

I will bring this post to the attention of the Board for a more authoritative response on the copyright / licensing question. These are just my personal opinions for now though Heather, Sebastian, Silje and I have discussed many of these issues so I can think they are probably representative.

The copyright holder is still openEHR? Does It have something to do
with the CC-BY-SA license?

The emerging view seems to be that any fork of an archetype, even if it just changes local ownership (namespace in ADL2.0) should probably result in change of copyright to the new owner with attribution to the previous owner. CC is a bit vague on when new copyright should be applied however.

In your case, this is a very significant change and I would expect copyright to change.

What license was decided we should use? Did we agree in which metadata
field should we store this?

We are adding a new ‘license’ attribute to other_details in ADL1.4 which will become a fully-fledged attribute in ADL2 …

other_details = <
[“licence”] = <“Creative Commons Attribution-ShareAlike 4.0 International License”>
[“revision”] = <“0.0.1-alpha”>
[“references”] = <" Derived from … “Adverse Reaction, draft archetype, National eHealth Transition Authority [Internet]. NEHTA Clinical Knowledge Manager. Authored: 08 Nov 2010. Available at: http://dcm.nehta.org.au/ckm/OKM.html#showarchetype_1013.1.868_7(accessed Jan 16, 2012).”>
[“build_uid”] = <“0043896f-d388-437e-ad46-472cb74ec56b”>
[“original_namespace”] = <“com.bosca”>
[“original_publisher”] = <“Bosca Enterprises”>
[“MD5-CAM-1.0.1”] = <“D5C7A064A7345211256376F748D97B6B”>
[“custodian_namespace”] = <“com.bosca”>
[“custodian_organisation”] = <“Bosca Enterprises”>

We are in the final stages of preparing a ‘beginner’s guide’ that explains this stuff in more detail.

Does the author change?

I would probably say no, if the clinical content is unchanged.

Probably the source archetype will also need
to be referenced somehow.

We would expect to see that attribution in References - see above

What else should be changed/added?

In the new world, you would need to change the namespaces, particularly as creating 13606 versions are definitely ‘new’ archetypes.

I assume that also a ‘generated’ field should be added (I know ADL 2
has this as a explicit field :wink: so for the moment probably the best is
to store everything we can’t put elsewhere in “other_details”.

I would expect ‘generated’ to apply to same ref model ADLS->ADL kinds of transforms only but interesting question. @Thomas ??

Can the resulting ADL be publicly distributed?

Yes, absolutely, as long as you do not try to re-sell the 13606 archetypes with a closed-source licence!!

Ian

The current proposed AOM 2 meta-data can be seen here <http://www.openehr.org/releases/trunk/UML/#Diagrams___18_1_83e026d_1422971258847_792963_30335&gt;\. Notes:

  * One thing we added due to CIMI, which we think is globally
    applicable is 'conversion_details' in RESOURCE_DESCRIPTION.
    Typically, an archetype with is_generated = true will have these
    conversion_details set. This should take care of the 13606
    conversion example.
  * See also ip_acknowledgements, which is how we will put in
    acknowledgements for e.g. SNOMED, LOINC etc.
  * The model doesn't yet include any changes corresponding to Silje and
    others ideas about a better model of translator details.

The current test example of an archetype with full meta- <https://github.com/openEHR/adl-archetypes/blob/master/ADL2-reference/features/meta_data/openehr-test_pkg-WHOLE.full_meta_data.v0.0.1.adls&gt;data is as follows.

archetype (adl_version=2.0.5; rm_release=1.0.2; generated)
     openehr-test_pkg-WHOLE.full_meta_data.v0.0.1

language
     original_language = <[ISO_639-1::en]>

description
     original_author = <
         ["name"] = <"Thomas Beale <thomas.beale@oceaninformatics.com>">
         ["organisation"] = <"Ocean Informatics <http://www.oceaninformatics.com>">
     >
     details = <
         ["en"] = <
             language = <[ISO_639-1::en]>
             purpose = <"This archetype demonstrates the use of governance meta-data.">
             use = <"This archetype should be used on a clear day with no wind.">
             misuse = <"This archetype should not be used around children or dogs.">
             keywords = <"governance", "test">
                original_resource_uri = <
                 ["resource A"] = <"Some resource available in the English language <http://aaa.bbb/path/to/resource&gt;&quot;&gt;
                 ["resource B"] = <"Some other resource available in the English language <http://aaa.bbb/path/to/resource&gt;&quot;&gt;
             >
         >
     >
     lifecycle_state = <"unmanaged">
     other_contributors = <"Marcus Aurelius <marcus@aurelius.net>", "Augustus Caesar <augustus@caesars_palace.net">
     original_namespace = <"org.archetypes-r-us">
     original_publisher = <"Archetype R Us">
     custodian_namespace = <"org.openehr">
     custodian_organisation = <"openEHR Foundation">
* licence = <"Creative Commons CC-BY <https://creativecommons.org/licenses/by/3.0/&gt;&quot;&gt;\*
     copyright = <"Copyright (c) 2014 openEHR Foundation">
     resource_package_uri = <http://www.openehr.org/ckm/path/to/package&gt;
* ip_acknowledgements = <**
** ["loinc"] = <"This content from LOINC® is copyright © 1995 Regenstrief Institute, Inc. and the LOINC Committee, and available at no cost under the license at http://loinc.org/terms-of-use&quot;&gt;\*\*
** ["snomedct"] = <"Content from SNOMED CT® is copyright © 2007 IHTSDO <ihtsdo.org>">**
** >**
** conversion_details = <**
** ["source_model"] = <"CEM model xyz <http://location.in.clinicalelementmodels.com>">**
** ["tool"] = <"cem2adl v6.3.0">**
** ["time"] = <"2014-11-03T09:05:00">**
** >**
* references = <
         ["1"] = <"Barthel Scale <http://en.wikipedia.org/wiki/Barthel_scale&gt;&quot;&gt;
         ["2"] = <"Barthel Index, the Internet Stroke Center <http://www.strokecenter.org/wp-content/uploads/2011/08/barthel.pdf&gt;&quot;&gt;
         ["3"] = <"O'Sullivan, Susan B; Schmitz, Thomas J (2007). Physical Rehabilitation, Fifth Edition. Philadelphia, PA: F.A. Davis Company. p. 385.">
     >
     other_details = <
         ["regression"] = <"PASS">

Can the resulting ADL be publicly distributed?

Yes, absolutely, as long as you do not try to re-sell the 13606 archetypes with a closed-source licence!!

It’s actually a little more strict than that; the SA (ShareAlike) clause in the Creative Commons BY-SA licence (which all the openEHR archetypes are licensed under) mandates that any derivative works are licensed under the same (or a compatible, but for practical purposes there aren’t any , see https://creativecommons.org/compatiblelicenses) licence, ie the CC-BY-SA licence.

Regards,
Silje